

HIGHLY ENANTIOSELECTIVE SYNTHESIS OF 3-HYDROXY-2-PHENYLPYPERIDINE VIA THE SHARPLESS AD-REACTION


Heinz Stadler* and Michael Bös*

Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd,
CH-4070 Basel, Switzerland


Abstract-Asymmetric dihydroxylation (AD) of the silyl enol ether (**3**) provided after hydrolysis the hydroxy ketone (**4**). Subsequent hydrogenation yielded the title compound (**1**) as a diastereomeric mixture. The *cis*-isomer is an important building block for the synthesis of potent NK₁ receptor antagonists.

INTRODUCTION

Selective and potent NK₁ receptor antagonists with a variety of distinct chemical structures have been disclosed.¹ Most prominent among these are 2-phenyl-3-benzyloxypiperidines (e.g. L-733060)² and 2-phenyl-3-benzyloxymorpholines (e.g. L-742311)³. While for the latter an efficient synthesis of the enantiomerically pure compound starting from phenylglycine has been described,⁴ the piperidine derivatives are only accessible *via* resolution of the racemic mixture. In addition, the published synthesis⁵ of the racemic heterocycle (**1**) provided in our laboratories the product in low yield. This report describes a synthetic protocol for **1** *via* the *Sharpless* AD reaction in high chemical and optical yield.



L-733060




L-742311

SYNTHESIS

The *Sharpless* AD reaction provides a versatile approach to oxy-substituted heterocycles such as lactones and lactams.⁶ Our approach to **1** is based on the AD reaction⁷ of the silyl enol ether (**3**), which is readily available from the ω -azidovalerophenone (**2**)⁸ by the method of *Ireland* with LDA-HMPA and TBDMS.⁹ For practical reasons the enol ether (**3**) can also be made simply by stirring the ketone (**2**) in CH₃CN in the presence of triethylamine and TBDMS¹⁰ yielding a Z/E ratio of 9/1. Dihydroxylation of this mixture with AD-Mix α gave the chiral hydroxy ketone (**4**) as the expected⁷ (*S*)-enantiomer in 69 % chemical yield and 83 % ee (¹H-NMR of *Mosher*-Ester). Reaction of **6** under hydrogenolytic conditions led to a mixture (4:1) of *cis*-**1a** and *trans*-**1b** in 96 % yield, which was separated by crystallisation⁵ to yield (*2S*, *3S*)-**1a** in 83% ee (GC). The absolute configuration of **1a**, and consequently also of **4**, was assigned by comparison of the optical rotation⁵ and the X-Ray analysis² published by the Merck Group. Applying the same sequence to the pure (*Z*)-Isomer (**3**) with AD-Mix β gave rise to (*2R*, *3R*)-**1a** in 95 % ee. The *cis*-isomer (**1a**) represents an important building block for the synthesis of potent and selective NK₁ receptor antagonists.

In summary the *Sharpless* AD reaction has once more been shown to be a valuable method in the field of enantioselective synthesis of heterocyclic compounds.



EXPERIMENTAL

(Z)- and (E)-(5-Azido-1-phenylpent-1-enyloxy)(*tert*-butyldimethyl)silanes (3)

To a mixture of 5-azido-1-phenylpentan-1-one (**2**) (10.6 g, 50 mmol), triethylamine (6.25 g, 62 mmol) and *tert*-butyldimethylchlorosilane (9.18 g, 62 mmol) a solution of NaI (9.25 g, 62 mmol) in acetonitrile (62 mL) was added. After stirring for 60 h CH_2Cl_2 (300 mL) and H_2O (200 mL) were added, the layers were separated and the aqueous phase was washed twice with CH_2Cl_2 (200 mL). The combined organic layers were dried (Na_2SO_4), filtered and evaporated. The residue was purified by flash chromatography (SiO_2 , hexanes/EtOAc 96 : 4) to give (Z)- and (E)-(5-azido-1-phenylpent-1-enyloxy)(*tert*-butyldimethyl)silane **A** and **B** (9 : 1) (13.42 g, 84 %) and **2** (1.64 g) each as a colorless oil.

An analytical sample was distilled by Kugelrohr-Distillation (150°/ 0.5 mmHg). $^1\text{H-NMR}$ (CDCl_3): δ 7.49 - 7.41 (m, 2 H, **A** and **B**), 7.38 - 7.27 (m, 3 H, **A** and **B**), 5.10 (t, $J = 8$, 0.9 H **A**), 5.02 (t, $J = 8$, 0.1 H **B**), 3.36 (t, $J = 8$, 1.8 H **A**), 3.29 (t, $J = 8$, 0.2 H **B**), 2.34 (dt, $J = 8$ and 8, 1.8 H **A**), 2.22 (dt, $J = 8$ and 8, 0.2 H **B**), 1.77 (tt, $J = 8$ and 8, 1.8 H **A**), 1.74 (tt, $J = 8$ and 8, 0.2 H **B**), 1.03 (s, 8.1 H **A**), 0.96 (s, 0.9 H **B**), 0.05 (s, 0.6 H **B**), 0.00 (s, 5.4 H **A**). Irradiation at δ 5.10: NOE 7.49-7.41 m (16%); IR (Neat): 2096 (N_3), 1649 ($\text{C}=\text{C}$), 1257 ($\text{Si}(\text{CH}_3)_3$), 840 ($\text{Si}(\text{CH}_3)_3$); MS (EI): 289 ($\text{M}-\text{N}_2$) $^+$, 232 (100, $\text{M}-(\text{N}_2-\text{C}_4\text{H}_9)^+$); Anal. Calcd for $\text{C}_{17}\text{H}_{27}\text{N}_3\text{O}_6$: C 64.31, H 8.57, N 13.24. Found: C 64.15, H 8.62, N 13.16.

The pure (Z)-silyl enol ether was prepared by using the method of Ireland⁹ with LDA /HMPA in THF.

(S)-(-)-5-Azido-2-hydroxy-1-phenylpentan-1-one (4)

To a well-stirred solution of (Z)- and (E)-(5-azido-1-phenylpent-1-enyloxy)(*tert*-butyldimethyl)silane (9:1) (4.78 g, 15 mmol) in $\text{H}_2\text{O}/t\text{-BuOH}$ (150 mL, 1:1) AD-mix α (21 g) and MeSO_2NH_2 (1.425 g, 15 mmol) were added at 0°C. The reaction mixture was stirred for 36 h at 0°C. Solid sodium sulfite (15 g) was added and the mixture stirred for an additional hour. After addition of CH_2Cl_2 , the layers were separated, the aqueous phase extracted with CH_2Cl_2 . The combined organic extracts were dried (MgSO_4), filtered and concentrated to give an oil, which was purified by flash chromatography to give (S)-(-)-5-azido-2-hydroxy-1-phenylpentan-1-one (2.3 g, 69%) as a colorless oil. An analytical sample was distilled in a Kugelrohr (150°/ 0.5 mmHg). $^1\text{H-NMR}$

(CDCl₃): δ 7.92 (d, $J = 7$, 2 H), 7.63 (dd, $J = 7$ and 7, 1 H), 7.52 (dd, $J = 7$ and 7, 2 H), 5.10 (ddd, $J = 8$, 6 and 3.5, 1 H), 3.75 (d, $J = 6$, OH), 3.32 (app. t, $J = 7$, 2 H), 2.09–1.50 (m, 4 H); IR (Neat): 3469 (OH), 2098 (N₃), 1682 (C=O); MS (EI): 219 (M⁺), 105 (100, C₇H₅O⁺); $[\alpha]_D^{20} = -10.3^\circ$ ($c = 0.99$, MeOH). Anal. Calcd for C₁₁H₁₃N₃O₂: C 60.26, H 5.89, N 19.17. Found: C 60.42, H 5.94, N 19.36.

The reaction carried out with the pure (Z)-Isomer and AD mix β yielded a product with $[\alpha]_D^{20} = +12.7^\circ$ ($c = 0.4$, MeOH).

Mosher-Ester preparation and enantiomeric excess determination

To a solution of (S)-(-)-5-azido-2-hydroxy-1-phenylpentan-1-one (50 mg, 0.228 mmol) ($[\alpha]_D^{20} = -10.4^\circ$ ($c = 0.99$, MeOH)) in CH₂Cl₂ (4 mL) *N,N'*-dicyclohexylcarbodiimide (52 mg, 0.251 mmol), 4-dimethylaminopyridine (0.3 mg, 0.0022 mmol) and (R)-(+)- α -methoxy- α -trifluoromethylphenylacetic acid (234 mg, 0.228 mmol) were added. After stirring for 6 h, the reaction mixture was filtered, diluted with CH₂Cl₂ (10 mL) and washed with 1N HCl, sat. NaHCO₃ and brine. The organic layer was dried (Na₂SO₄), filtered and evaporated. ¹H-NMR-Analysis (CH₃O-Signal: δ 3.58 vs. δ 3.66) indicated an ee of 88 %.

(2S,3S)-(+)-2-Phenylpiperidin-3-ol (1)

A mixture of (S)-(-)-5-azido-2-hydroxy-1-phenylpentan-1-one ($[\alpha]_D^{20} = -10.4^\circ$ ($c = 0.99$, MeOH) (1.75 g, 7.9 mmol) and Pd on charcoal (100 mg, 5%) in ethanol (20 mL) was hydrogenated for 16 h. The catalyst was filtered off and the solvent evaporated to give a colorless oil (1.35 g, 96%). ¹H-NMR and anal. GC (dimethylpolysilicon) indicated a *cis* to *trans* ratio of 4:1. The *cis*-isomer was isolated *via* the tosylate as described⁵ to give (+)-(2S,3S)-2-phenylpiperidin-3-ol (0.94 g, 67 %) as colorless crystals, mp 92–93.5°. ¹H-NMR (CDCl₃): δ 7.43–7.23 (m, 5 H), 3.85 (br s, 1 H), 3.78 (br s, 1 H), 3.20 (dddd, $J = 12$, 4, 2 and 2, 1 H), 2.80 (ddd, $J = 12$, 12 and 3, 1 H), 2.09 (dm, $J = 12$, 1 H), 1.87 (dddd, $J = 12$, 12, 12, 4 and 4, 1 H), 1.68 (dddd, $J = 12$, 12, 4 and 2, 1 H), 1.50 (dm, $J = 12$, 1 H); IR (Nujol): 3253 (OH), 1603 (Ar), 1499 (Ar), 1062 (OH), 718 (Ar). MS (EI): 177 (M⁺), 132, 120, 104 (100). $[\alpha]_D^{20} = +81.5^\circ$ ($c = 0.68$, MeOH). (lit.,⁵ ($[\alpha]_D^{20} = +98.5^\circ$ ($c = 1$, MeOH)). Anal. GC on a chiral Phase (BGB-176) indicated an ee of 83 %. Anal. Calcd for C₁₁H₁₅NO: C 74.54, H 8.53, N 7.90. Found: C 74.25, H 8.60, N 7.87.

The reaction carried out with (*R*)-(-)-5-azido-2-hydroxy-1-phenylpentan-1-one ($[\alpha]_D^{20} = +12.7^\circ$ ($c = 0.4$, MeOH)) yielded a product with ($[\alpha]_D^{20} = -93^\circ$ ($c = 0.4$, MeOH)) (lit.⁵ : $[\alpha]_D^{20} = -97.2^\circ$ ($c = 1$, MeOH)). Anal.GC on a chiral phase (BGB-176) indicated an ee of 95.3 %.

REFERENCES AND NOTES

- * New address: Boehringer-Ingelheim (Canada) Ltd., Bio-Méga Research Division, 2100 Cunard Street, Laval (Québec), H75265 Canada
1. C. J. Swain, in *Progress in Medicinal Chemistry*, Vol. 35, 1998, 57.
 2. T. Harrison, B. J. Williams, C. J. Swain, and R. G. Ball, *Bioorg. Med. Chem. Lett.*, 1994, **4**, 2545.
 3. J.J. Hale, S. G. Mills, M. MacCoss, S. K. Shah, H. Qi, D. J. Mathre, M. A. Cascieri, S. Sadowski, C. D. Strader, D. E. MacIntyre, and J. M. Metzger, *J. Med. Chem.*, 1996, **39**, 1760.
 4. M. S. Ashwood, I. F. Cottrell, and A. J. Davies, *Tetrahedron: Asymmetry*, 1997, **8**, 957.
 5. R. Baker, T. Harrison, C. J. Swain, and B. J. Williams, European Patent Application 0 528 495 A1 (*Chem. Abstr.*, 1993, **119**, 177 122).
 6. a) Z.-M. Wang, X.-L. Zhang, and K. B. Sharpless, *Tetrahedron Lett.*, 1992, **33**, 6407;
b) T. J. Hodgkinson and M. Shipman, *Synthesis*, **1998**, 1141.
 7. T. Hashiyama, K. Morikawa, and K. B. Sharpless, *J. Org. Chem.*, 1992, **57**, 5067.
 8. M. Vaultier, P. H. Lambert, and R. Carrié, *Bull. Soc. Chim. Fr.*, **1986**, 83.
 9. R. E. Ireland, R. H. Müller, and A. K. Willard, *J. Am. Chem. Soc.*, 1986, **98**, 2868.
 10. Ph. Cazeau, F. Moulines, O. Laporte, and F. Duboudin, *J. Organomet. Chem.*, 1989, **201**, C9.

Received, 18th January, 1999